Primmune Therapeutics Strengthens Leadership Team with Key Appointments
SAN DIEGO--(BUSINESS WIRE)--Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development.
“The appointments of Rich, Scott and Randy to the team build on the recent close of our Series A financing to support the development of PRTX007 as a therapeutic-adjuvant for viral diseases and cancer,” said Charlie McDermott, Chairman and Chief Executive Officer of Primmune Therapeutics. “Rich, Scott, and Randy have very deep domain experience in their respective functions and have taken multiple programs from early stage through global commercialization. In addition, they have been instrumental in the build out of successful startup organizations, thrived in large organizations, and are driven to address unmet medical needs with innovative therapeutics.”
Richard Daniels brings more than 25 years of experience in the pharmaceutical and biotech industry covering all stages of product development and commercialization in multiple therapeutic areas. Prior to joining Primmune Therapeutics, Mr. Daniels was Senior Vice President of Clinical Operations and R&D Planning at Intercept Pharmaceuticals where he was responsible for managing a ~$180M annual R&D budget across multiple development and in-market programs supporting the company’s liver-disease focus. Prior to Intercept Pharmaceuticals, Mr. Daniels spent 15 years at Amgen in increasing roles of responsibility, including the last 5 years as Executive Director and Oncology Therapeutic Area Lead where he was responsible for managing development and life-cycle activities for a portfolio of 20+ pipeline and marketed assets. Earlier in Mr. Daniels’ career, he held various scientific positions at Genicon Sciences (acquired by Life Technologies) and Agouron Pharmaceuticals (acquired by Pfizer). Mr. Daniels earned a B.S. in microbiology from the University of California, San Diego.
Scott Zook brings more than 27 years of drug development experience in the pharmaceutical industry consisting of establishing and directing CMC strategy and activities, developing global supply chains and managing a wide range of drug candidates across all regulatory phases. Prior to joining Primmune Therapeutics, Mr. Zook was Vice President of CMC at Neurocrine Biosciences where he was responsible for managing the development and manufacturing efforts across a wide range of therapeutic areas, including neurology, gene therapy, endocrinology, pediatric and adult epilepsy and neuro-psychiatric conditions and two NDA approvals. Prior to joining Neurocrine Biosciences, Mr. Zook was a scientist at Agouron Pharmaceuticals (acquired by Pfizer) where he led the API efforts on VEGF oncology and VEGF ophthalmology products. Mr. Zook earned his M.Sc. in synthetic organic chemistry and B.Sc. in organic chemistry from the University of Saskatchewan.
Randy Adams brings more than 25 years of commercial experience in the specialty pharmaceutical, biological and medical device industry. Prior to joining Primmune Therapeutics, Mr. Adams was Vice President of Commercial at Equillium where he was responsible for strategic planning related to the company’s lead candidate itolizumab. Prior to joining Equillium, Mr. Adams served as Senior Vice President of Commercial at Impact Biomedicines (acquired by Celgene) where he was responsible for commercial readiness activities to support the launch of fedratinib, a selective JAK2 inhibitor for the treatment of myelofibrosis. Prior to joining Impact Biomedicines, Mr. Adams was Executive Vice President and a founding partner at Carling Communications (acquired by Fishawack Health), where he was instrumental in building a global strategic consulting and medical communications agency and was a strategic advisor on multiple specialty product launches. Prior to Carling Communications, Mr. Adams held roles of increasing responsibility at Allergan, including Director of Marketing, where he was responsible for leading a $1 billion dry eye portfolio and was instrumental in the launch and successful commercialization of RESTASIS®. Mr. Adams earned a B.A. in business administration from Georgia College & State University.
About Primmune Therapeutics
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com.
Westwicke, an ICR company